Sinil Pharmaceutical (A012790) Stock Overview
Manufactures and sells pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
A012790 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Sinil Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,110.00 |
| 52 Week High | ₩7,200.00 |
| 52 Week Low | ₩5,640.00 |
| Beta | 0.61 |
| 1 Month Change | 0.33% |
| 3 Month Change | 3.91% |
| 1 Year Change | -4.68% |
| 3 Year Change | -26.21% |
| 5 Year Change | -60.45% |
| Change since IPO | 465.15% |
Recent News & Updates
Recent updates
Little Excitement Around Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Earnings
Aug 12
Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials Driving The Negative Sentiment?
Mar 11Is Sinil Pharmaceutical's (KOSDAQ:012790) 122% Share Price Increase Well Justified?
Feb 13
Could The Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790) Ownership Structure Tell Us Something Useful?
Jan 17Sinil Pharmaceutical's (KOSDAQ:012790) Earnings Are Growing But Is There More To The Story?
Dec 22Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Nov 26Shareholder Returns
| A012790 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.3% | -1.4% | 6.3% |
| 1Y | -4.7% | 40.7% | 125.8% |
Return vs Industry: A012790 underperformed the KR Pharmaceuticals industry which returned 41.3% over the past year.
Return vs Market: A012790 underperformed the KR Market which returned 130% over the past year.
Price Volatility
| A012790 volatility | |
|---|---|
| A012790 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A012790 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A012790's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | n/a | Mi-Keun Jung | www.sinilpharm.com |
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin supplements; and quasi-drugs for yellow dust, bacteria blocking, etc. In addition, it is involved in the real estate rental services.
Sinil Pharmaceutical Co., Ltd. Fundamentals Summary
| A012790 fundamental statistics | |
|---|---|
| Market cap | ₩69.51b |
| Earnings (TTM) | ₩7.53b |
| Revenue (TTM) | ₩80.56b |
Is A012790 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A012790 income statement (TTM) | |
|---|---|
| Revenue | ₩80.56b |
| Cost of Revenue | ₩47.13b |
| Gross Profit | ₩33.44b |
| Other Expenses | ₩25.91b |
| Earnings | ₩7.53b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 661.99 |
| Gross Margin | 41.50% |
| Net Profit Margin | 9.35% |
| Debt/Equity Ratio | 0% |
How did A012790 perform over the long term?
See historical performance and comparisonDividends
Does A012790 pay a reliable dividends?
See A012790 dividend history and benchmarks| Sinil Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Apr 30 2026 |
| Days until Ex dividend | 106 days |
| Days until Dividend pay date | 16 days |
Does A012790 pay a reliable dividends?
See A012790 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 01:22 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinil Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.